February 5, 2021
Bimekizumab Superior to Ustekinumab for Plaque Psoriasis
FRIDAY, Feb. 5, 2021 (HealthDay News) — For moderate-to-severe plaque psoriasis, bimekizumab is more efficacious than ustekinumab and placebo, according to a study published in the Feb. 6 issue of The Lancet. Kristian Reich, M.D., from the University Medical Center Hamburg-Eppendorf in Germany, and colleagues compared the efficacy and safety of bimekizumab with placebo and...
Residential Segregation May Worsen NSCLC Outcomes for Black Patients
Black patients are more likely to present with advanced non-small cell lung cancer (NSCLC) and are less likely to receive surgery at higher residential segregation levels, according to a study presented at the annual meeting of the Society of Thoracic Surgeons, held virtually from Jan. 29 to 31. Chandler Annesi, from the Boston University School...